UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialists

BMJ Oncology, 2024-06, Vol.3 (1), p.e000429

Bangs, Rick

2024

Link zum Volltext

Verfügbarkeit prüfen

From the other side: The patient perspective on cancer clinical trials

Urologic oncology, 2019-05, Vol.37 (5), p.331-335

2019

Link zum Volltext

Verfügbarkeit prüfen

Future Directions in Bladder Cancer Treatment and Research—The Patient Advocates’ Perspective

Hematology/oncology clinics of North America, 2021-06, Vol.35 (3), p.655-664

2021

Link zum Volltext

Verfügbarkeit prüfen

Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces

JNCI : Journal of the National Cancer Institute, 2022-08, Vol.114 (8), p.1059-1064

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4608-TPS4608

2023

Link zum Volltext

Verfügbarkeit prüfen

Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13599-e13599

2023

Link zum Volltext

Verfügbarkeit prüfen

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18529-e18529

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS581-TPS581

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2018-05, Vol.36 (15), p.1521-1539

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient‐centered prioritization of bladder cancer research

Cancer, 2018-08, Vol.124 (15), p.3136-3144

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4608-TPS4608

2022

Link zum Volltext

Verfügbarkeit prüfen

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

JNCI : Journal of the National Cancer Institute, 2018-06, Vol.110 (6), p.553-559

2018

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical cancer research, 2021-05, Vol.27 (9), p.2435-2441

2021

Link zum Volltext

Verfügbarkeit prüfen

Interventions addressing health-related social needs among patients with cancer

JNCI : Journal of the National Cancer Institute, 2024-04, Vol.116 (4), p.497-505

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

European urology, 2023-12, Vol.84 (6), p.536-544

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS591-TPS591

2022

Link zum Volltext

Verfügbarkeit prüfen

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4508-4508

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical cancer research, 2024-01, Vol.30 (2), p.444

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4541-4541

2021

Link zum Volltext

Verfügbarkeit prüfen

Bladder cancer patient and provider perspectives on smoking cessation

Urologic oncology, 2023-11, Vol.41 (11), p.457.e9-457.e16

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.424-424

2021

Link zum Volltext

Verfügbarkeit prüfen

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.536-536

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European urology, 2023-09, Vol.84 (3), p.341-347

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialists

From the other side: The patient perspective on cancer clinical trials

Future Directions in Bladder Cancer Treatment and Research—The Patient Advocates’ Perspective

Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Patient‐centered prioritization of bladder cancer research

A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Interventions addressing health-related social needs among patients with cancer

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

P2-03 SWOG S1011–SUBGROUP ANALYSIS OF THE PHASE III SURGICAL TRIAL TO EVALUATE THE BENEFIT OF A STANDARD VERSUS AN EXTENDED LYMPHADENECTOMY PERFORMED AT TIME OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011)

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)

Bladder cancer patient and provider perspectives on smoking cessation

Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results

Suchergebnisse filtern